Home
»
Press Room
»
Residual DNA Testing Market To Reach $525.3Mn By 2033

Residual DNA Testing Market To Reach $525.3 Million By 2033

April 2026 | Report Format: Electronic (PDF)

Residual DNA Testing Market Growth & Trends

The global residual DNA testing market size is projected to reach USD 525.3 million by 2033, growing at a CAGR of 6.8% from 2026 to 2033, according to a new report by Grand View Research, Inc. The global residual DNA testing market is experiencing steady growth, driven by the increasing regulatory emphasis on product safety and quality in biopharmaceutical manufacturing. Residual DNA testing plays a critical role in ensuring that host cell DNA impurities are within permissible limits in biologics, vaccines, and cell & gene therapies.

The rapid expansion of biologics and biosimilars, along with a growing pipeline of cell and gene therapies across oncology, rare diseases, and infectious disorders, is further fueling market demand. Increasing outsourcing to CROs and CDMOs, coupled with rising investments in biopharmaceutical R&D, is boosting the adoption of residual DNA testing services. Moreover, the growing focus on vaccine development and large-scale biologics production is reinforcing the need for robust contamination monitoring, thereby supporting market growth.

Technological advancements, including automation, high-throughput screening, and improved assay sensitivity, are enhancing the efficiency, accuracy, and reproducibility of residual DNA detection. Integration of advanced analytics and streamlined workflows also enabling faster turnaround times and regulatory compliance in both research and commercial manufacturing settings. As a result, residual DNA testing continues to be a vital component of quality control frameworks, supporting the global transition toward safer, more effective biologics and next-generation therapeutics.

key Request a free sample copy or view report summary: Residual DNA Testing Market Report

Residual DNA Testing Market Report Highlights

By product & service, consumables accounted for the largest market share of 41.1% in 2025. The high frequency of testing across biopharmaceutical production workflows drives continuous demand for kits, reagents, standards, and assay components. As residual DNA testing is routinely performed at multiple stages of manufacturing and quality control, the recurring nature of consumables usage, along with increasing assay standardization and automation, continues to support segment dominance.
By test type, final product testing dominated the market in 2025 with a share of 45.0%. This is primarily due to stringent regulatory requirements mandating the quantification of residual host cell DNA in finished biologics before commercialization. Ensuring product safety, purity, and compliance with guidelines set by regulatory authorities such as the U.S. Food and Drug Administration and European Medicines Agency has made final product testing a critical and non-negotiable step in biomanufacturing processes.
By technology, PCR held the leading market share of 42.4% in 2025. PCR-based methods, particularly quantitative PCR (qPCR), are widely preferred due to their high sensitivity, specificity, and ability to detect trace levels of residual DNA. Their established use, regulatory acceptance, and compatibility with high-throughput workflows make PCR the gold standard technology in residual DNA analysis.
By application, monoclonal antibodies represented the largest segment in 2025. The widespread production of monoclonal antibody-based therapeutics, driven by their extensive use in oncology, autoimmune diseases, and chronic conditions, has significantly increased the need for rigorous residual DNA testing to ensure product safety and regulatory compliance.
By end-user, pharmaceutical & biotechnology companies captured the largest share of 59.6% in 2025. Their dominance is attributed to the growing pipeline of biologics, biosimilars, and advanced therapies, along with substantial investments in in-house manufacturing and quality control capabilities. The increasing emphasis on regulatory compliance and product safety further drives the adoption of residual DNA testing within these organizations.

Residual DNA Testing Market Segmentation

Grand View Research has segmented the global residual DNA testing market on the basis of product & service, test type, technology, application, end-user, and region:

Residual DNA Testing Product & Service Outlook (Revenue, USD Million, 2021 - 2033)